menu
    • menu
    [{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Klinge Pharma \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Klinge Pharma \/ Coherus BioSciences"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Klinge Pharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Klinge Pharma \/ MS Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Klinge Pharma

    Menu

    Klinge Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Klinge Pharma

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MS Pharma Partners for FYB203 Biosimilar Commercialization in MENA Region

                            Details : MS Pharma becomes a partner for the commercialization of FYB203, Formycon’s Biosimilar to Eylea® (Aflibercept), in the MENA Region for the treatment of neovascular age-related macular degeneration.

                            Brand Name : FYB203

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 14, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Klinge Pharma

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

                            Details : FYB203, a biosimilar candidate to Eylea (aflibercept), which Klinge Biopharma has in-licensed from the German biosimilar developer Formycon AG, is being evaluated in a Phase 3 clinical trial in patients with Neovascular (wet) Age-Related Macular Degenera...

                            Brand Name : FYB203

                            Molecule Type : Large molecule

                            Upfront Cash : $32.5 million

                            January 09, 2023

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth